Voyager Therapeutics (VYGR) Net Cash Flow (2014 - 2026)
Voyager Therapeutics (VYGR) posted Net Cash Flow of -$22.0 million for Q1 2026, down 227.11% sequentially from $17.3 million in Q4 2025, and down 748.94% YoY from $3.4 million in Q1 2025.
Voyager Therapeutics (VYGR) Net Cash Flow (2014 - 2026) Analysis & Trends
Voyager Therapeutics has reported Net Cash Flow for 13 years, with the latest figure at -$22.0 million in Q1 2026.
- Quarterly Net Cash Flow fell 748.94% year-over-year to -$22.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$31.6 million (up 53.78% YoY) and the FY2025 annual result came in at -$6.2 million, down 261.34% from the prior year.
- Net Cash Flow slipped to -$22.0 million in Q1 2026 per VYGR's latest filing, from $17.3 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $169.4 million in Q1 2023 and troughed at -$179.0 million in Q3 2023.
- A 5-year average of -$4.3 million and a median of $3.4 million in 2025 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Net Cash Flow tumbled 119673.33% in 2022, then jumped 1072.87% in 2023.
- Over 5 years, Net Cash Flow stood at $2.1 million in 2022, then surged by 68.32% to $3.5 million in 2023, then sank by 1264.96% to -$41.2 million in 2024, then surged by 142.03% to $17.3 million in 2025, then sank by 227.11% to -$22.0 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$22.0 million, $17.3 million, and $3.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.89 Bn | 131.04 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.05 Bn | 78.06 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.56 Bn | 60.38 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.46 Bn | 50.32 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 27.70 Bn | 9.30 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 225.59 Mn |
| 10 | Voyager Therapeutics | 204.95 Mn | 88.62 Mn | - | -7.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.55 Mn |
| Jun 30, 2026 | -7.55 Mn |
| Mar 31, 2026 | -21.99 Mn |
| Mar 31, 2026 | -21.99 Mn |
| Dec 31, 2025 | 17.30 Mn |
| Dec 31, 2025 | 17.30 Mn |
| Sep 30, 2025 | 3.93 Mn |
| Sep 30, 2025 | 3.93 Mn |
| Jun 30, 2025 | -30.82 Mn |
| Jun 30, 2025 | -30.82 Mn |
| Mar 31, 2025 | 3.39 Mn |
| Mar 31, 2025 | 3.39 Mn |
| Dec 31, 2024 | -41.16 Mn |
| Dec 31, 2024 | -41.16 Mn |
| Sep 30, 2024 | 36.40 Mn |
| Sep 30, 2024 | 36.40 Mn |
| Jun 30, 2024 | -66.95 Mn |
| Jun 30, 2024 | -66.95 Mn |
| Mar 31, 2024 | 75.56 Mn |
| Mar 31, 2024 | 75.56 Mn |